Overview

A Safety, Tolerability, And Pharmacokinetic Trial With CVX-241 In Patients With Advanced Solid Tumors

Status:
Terminated
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if CVX-241 (PF-05057459) is safe and tolerable when given as weekly infusions to adult patients with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Endothelial Growth Factors